Scenarios that move TMO
Thermo Fisher Scientific Inc Common Stock
Scenarios that move TMO: 30 analyses, 27 positive, 3 negative.
- · Ascendis Pharma receives positive CHMP opinion for TransCon CNP — ▲ · impact +10 · confidence low · horizon quarters
- · OPKO Health to sell BioReference assets to Labcorp for $722M — ▲ · impact +19 · confidence medium · horizon quarters
- · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▼ · impact -6 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▲ · impact +35 · confidence low · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▲ · impact +18 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +18 · confidence medium · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +10 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▲ · impact +5 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▲ · impact +18 · confidence medium · horizon weeks
- · ◇ What if… Plague outbreak in Russia continues and spreads further — ▲ · impact +45 · confidence high · horizon weeks
- · Spyre Therapeutics prices $350 million public stock offering — ▲ · impact +14 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▲ · impact +30 · confidence low · horizon weeks
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▲ · impact +15 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +9 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▲ · impact +26 · confidence low · horizon quarters
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▲ · impact +24 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▲ · impact +46 · confidence medium · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▲ · impact +14 · confidence low · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▲ · impact +10 · confidence low · horizon quarters
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▲ · impact +18 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▲ · impact +15 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▲ · impact +37 · confidence medium · horizon weeks
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▲ · impact +10 · confidence low · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▲ · impact +20 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +42 · confidence low · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▲ · impact +22 · confidence low · horizon quarters
- · Exosens raises 2026 targets on stronger production and sales momentum — ▲ · impact +15 · confidence low · horizon quarters
- · Sion cuts workforce nearly half after CF study failure — ▼ · impact -14 · confidence medium · horizon quarters
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▼ · impact -8 · confidence low · horizon quarters
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▲ · confidence low